A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
Related Experiment Video
Updated: Dec 5, 2025
Yukun Wang1, Dejiu Kong1, Chaokun Wang1
1Henan Key Laboratory of Cancer Epigenetics; Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Objective:
We aimed to evaluate immune-related adverse events occurring in clinical trials of anti-programmed cell death 1 (PD-1) drugs, compared with control treatments, including chemotherapy, targeted drugs, or placebo. Further we compared the occurrence of immune -related events in patients treated with different anti-PD-1 drugs.
Data Sources:
Randomized controlled trial (RCT) data were sourced from PubMed, Embase, and the Cochrane Central Register of Controlled Trials combined with https://clinicaltrials.gov.
Methods:
Randomized controlled trial of anti-PD-1 drugs compared with control treatments published between January 1, 1970 and March 1,2019, were searched and data on trial patient characteristics, and adverse events extracted, reviewed, and subjected to meta-analysis.
Results:
Eighteen Randomized controlled trials were included in our study. The Randomized controlled trials compared nivolumab (n = 12), pembrolizumab (n = 6), with chemotherapy (n = 13), targeted drugs (n = 2), or placebo (n = 3). Compared with the control group, the risk of any immune-related adverse events in patients treated with anti-PD-1 drugs was increased (RR, 2.65; 95% confidence interval, 1.84-3.83; P < 0.00001). Of the immune-related adverse events, the risk rates of pneumonitis (risk ratio, 2.10; 95% CI, 0.85-5.18), colitis (2.96;1.62-5.38), hypophysitis(4.79;1.54-14.89), hypothyroidism(7.87;5.36-11.57), hyperthyroidism (7.03;4.35-11.34), rash (1.58;0.98-2.54), pruritus (2.28; 1.38-3.76), and hepatitis (9.31;2.18-39.85) were increased by anti-PD-1 drugs. Further, the risk of immune-related adverse events was similar for patients treated with pembrolizumab and nivolumab (P = 0.14).
Conclusions:
In addition to previously reported organ-specific immune-related adverse events, we found that the risk of hyperthyroidism was also increased, in anit-PD-1-treated patients, relative to control treatments. The risk of total immune-related adverse events, was similar for pembrolizumab and nivolumab.
Insights
Anti-programmed cell death 1 (PD-1) drugs significantly increase immune-related adverse events compared to control treatments. The risk of hyperthyroidism is also elevated, with similar event rates between pembrolizumab and nivolumab.
Area of Science:
- Immunology
- Oncology
- Clinical Pharmacology
Background:
- Immune-related adverse events (irAEs) are common with immune checkpoint inhibitors.
- Understanding the specific irAEs associated with anti-programmed cell death 1 (PD-1) therapies is crucial for patient management.
Purpose of the Study:
- To evaluate the incidence of irAEs in clinical trials of anti-PD-1 drugs versus control treatments.
- To compare irAE occurrence between different anti-PD-1 agents, specifically nivolumab and pembrolizumab.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Data sourced from PubMed, Embase, Cochrane Library, and clinicaltrials.gov.
- Included RCTs comparing anti-PD-1 drugs with chemotherapy, targeted drugs, or placebo, published up to March 2019.
Main Results:
- Eighteen RCTs involving 12 nivolumab and 6 pembrolizumab trials were analyzed.
- Anti-PD-1 therapy significantly increased the risk of any irAE (RR, 2.65; P < 0.00001) compared to controls.
- Increased risks were observed for pneumonitis, colitis, hypophysitis, hypothyroidism, hyperthyroidism, rash, pruritus, and hepatitis. The risk of hyperthyroidism was notably increased.
- The incidence of irAEs was similar between pembrolizumab and nivolumab (P = 0.14).
Conclusions:
- Anti-PD-1 drugs substantially elevate the risk of irAEs, including hyperthyroidism.
- Nivolumab and pembrolizumab demonstrate comparable safety profiles regarding the overall risk of irAEs.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...


